Innovation Pharmaceuticals (Innovation Pharmaceuticals) Short Percentage of Float

View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Innovation Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, Innovation Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's Short Percentage of Float falls into.

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880

Website

http://www.ipharminc.com

Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.

Executives

Arthur Peter Bertolino	officer: Pres. & Chief Medical Officer	C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness	officer: Vice President	100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin	director	C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor	director	17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter	director	7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich	director, 10 percent owner, officer: Chief Financial Officer	C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon	director, 10 percent owner, officer: President-Chief Scient.Officer	10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans	director, officer: Chief Executive Officer	17 IRVING PLACE, PELHAM NY 10803